DRG Epidemiology's coverage of T2D comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of T2D for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.

DRG Epidemiology's T2D forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with T2D?
  • Of all people with T2D, how many in each country have been formally diagnosed?
  • Of all people diagnosed with T2D, how many in the major pharmaceutical markets across the world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of T2D over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, DRG Epidemiology forecasts 36 T2D patient populations, as follows:

  • Total FPG criteria prevalent cases
  • Total FPG or HbA1c criteria prevalent cases
  • Total FPG criteria incident cases
  • Diagnosed prevalent cases
  • Diagnosed drug-treated prevalent cases
  • Diagnosed drug-treated controlled prevalent cases
  • Lifetime DALYs gained
  • … and many more (details available on request).

Note: coverage may vary by country.

Table of contents

  • Type 2 Diabetes - Epidemiology - Emerging Markets Data
    • Introduction
      • Key Findings
        • Prevalence of Type 2 Diabetes per 1,000 Among People Aged 20+ in 2018 and 2028
    • Epidemiology Data
    • Methods
      • Total Prevalent Cases
      • Diagnosed Prevalent Cases of T2D
      • Drug-Treated Cases of Type 2 Diabetes
      • Controlled Prevalent Cases of Type 2 Diabetes
      • Total Incident Cases
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of T2D
        • Studies Excluded from the Analysis of T2D
      • Risk/Protective Factors
        • Risk/Protective Factors for T2D
      • Bibliography

Author(s): Joseph Granato, M.P.H.

Joseph Granato, M.P.H., is a senior epidemiologist at DRG, part of Clarivate. Before joining DRG, he worked with the Monroe County Health Department on the surveillance of reportable diseases, including dengue fever. He received his M.P.H. from Des Moines University, where he worked on several population health projects, including tick-borne diseases. He also holds a B.S. in animal science from the University of Tennessee.

Related Reports

Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

View Details

Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

View Details

Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

View Details

Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

View Details